How Does Semaglutide Work? The Mechanism Explained

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist, a drug that mimics a hormone called GLP-1 (glucagon-like peptide-1) that your gut naturally produces after eating. It is approved by the FDA under the brand names Ozempic® (type 2 diabetes and cardiovascular risk reduction), Wegovy® (obesity), and Rybelsus® (oral type 2 diabetes). As of 2026 semaglutide comes as both an injection and a pill: the injectable Ozempic and Wegovy pens are now joined by the Ozempic pill (oral, 1.5/4/9mg for type 2 diabetes, launched May 4 2026 as the reformulated successor to Rybelsus) and the Wegovy pill (oral, 25mg for weight management, FDA-approved December 22 2025). Compounded semaglutide follows the same mechanism as the brand-name products.

For background on what semaglutide is, its approved indications, and brand name differences, see the what is semaglutide guide. The focus here is the mechanism: how it actually works inside your body. For clinical weight loss outcomes, see semaglutide weight loss results. For a full overview of semaglutide resources, visit the semaglutide hub.

What Is GLP-1, and Why Does Semaglutide Mimic It?

GLP-1 (glucagon-like peptide-1) is a hormone secreted by specialised cells in the gut lining called L-cells. Your body releases it within minutes of eating. It signals the pancreas to release insulin, tells the stomach to slow down, and sends fullness cues to the brain. It is a natural part of why you stop eating when you've had enough.

The problem: native GLP-1 has a half-life of just two minutes. An enzyme called DPP-4 (dipeptidyl peptidase-4) breaks it down almost immediately after release. Its effects are real but fleeting. Semaglutide shares 94% of GLP-1's structure, close enough to activate the same receptors, but is engineered to survive in the body for about seven days instead of two minutes. [9]

That engineering is what makes once-weekly dosing possible. The pharmacokinetic details are covered later. First, the three main places semaglutide acts: the pancreas, the gastrointestinal tract, and the brain.

How Semaglutide Works in the Pancreas

The pancreas is where semaglutide's blood sugar effects happen. It has GLP-1 receptors (GLP-1R) on two key cell types: beta cells, which make insulin, and alpha cells, which make glucagon (a hormone that raises blood sugar).

Insulin secretion from beta cells

When semaglutide binds to GLP-1R on a beta cell, it activates a signalling cascade: GLP-1R → Gs protein → adenylate cyclase → increased intracellular cAMP (cyclic AMP). [2]

That cAMP rise triggers two parallel insulin-release pathways. The first goes through PKA (protein kinase A), which promotes exocytosis (the release of insulin-containing vesicles from inside the beta cell). The second goes through EPAC (exchange protein activated by cAMP), which closes ATP-sensitive potassium channels, allowing calcium to flood in, which depolarises the cell membrane and amplifies insulin release further. [2]

The glucose-dependent safety advantage

This insulin release only happens when blood glucose is elevated. When blood sugar is normal or low, the signalling cascade doesn't reach the threshold needed to trigger exocytosis. This glucose-dependency is why semaglutide carries a very low risk of hypoglycaemia (dangerously low blood sugar) when used alone, unlike older diabetes medications that push insulin release regardless of glucose levels. [1]

Glucagon suppression from alpha cells

On pancreatic alpha cells, semaglutide suppresses glucagon release. Glucagon normally tells the liver to release stored glucose into the bloodstream between meals. Reducing glucagon lowers this hepatic glucose output, which contributes to better blood sugar control independently of insulin. [2]

How Semaglutide Slows Gastric Emptying

Gastric emptying is the process by which food moves from your stomach into the small intestine. Semaglutide slows this process through GLP-1R activation in the gastrointestinal tract and via the vagus nerve, the main nerve connecting gut to brain. The specific effects include: relaxation of the gastric fundus (the upper portion of the stomach), reduced antral contractility (less churning), and increased pyloric tone (tightening of the valve that controls flow into the small intestine). [4]

The result: food sits in your stomach longer. Nutrients absorb more slowly, blunting the post-meal glucose spike. You feel full for longer after eating. A randomised controlled trial measuring semaglutide 2.4 mg vs placebo quantified this: gastric emptying (measured by paracetamol absorption rate) slowed by approximately 8% vs placebo in the first five hours after breakfast. The same trial found that semaglutide reduced total caloric intake by approximately 24% compared to placebo. [5]

⚠️ Why nausea happens

Nausea is the most common side effect of semaglutide, particularly during dose escalation. Two mechanisms contribute. First: gastric emptying delay means food stays in the stomach longer than your body expects, especially after a large or fatty meal, which triggers a nausea response. Second: the area postrema, a small structure in the brainstem that detects potentially toxic substances in the blood, has GLP-1 receptors that semaglutide can directly activate (more on this in the brain section below). [4]

Nausea typically improves after a few weeks at each dose as the GI tract adapts. Smaller, lower-fat meals reduce the effect. Full management strategies are covered in the semaglutide side effects guide.

⚠️ Surgery and anaesthesia: a practical note

Because semaglutide substantially slows gastric emptying, there is a clinically relevant aspiration risk if you undergo surgery while the drug is active. Gastric effects can persist for approximately 23 days after stopping semaglutide, the time it takes for plasma levels to fall below 10% of steady-state. [11] If you have planned surgery, tell your anaesthetist you are using semaglutide and discuss timing with your doctor. Current anaesthesia guidelines address pre-operative semaglutide management specifically.

How Semaglutide Affects the Brain

Most consumer descriptions reduce semaglutide's appetite suppression to "it acts on the hypothalamus." The actual primary entry point is the brainstem, specifically two structures that sit outside the blood-brain barrier.

The area postrema and nucleus tractus solitarius (NTS)

The area postrema is a small structure at the base of the brainstem that sits outside the blood-brain barrier. It continuously monitors the bloodstream for signs of toxic exposure, which is why it triggers vomiting when it detects toxins. It is densely populated with GLP-1 receptors, and semaglutide can reach it directly from circulation. Activation here contributes to both the appetite-suppressing and nausea-producing effects.

Adjacent to the area postrema is the nucleus tractus solitarius (NTS), a relay hub in the brainstem that integrates satiety signals arriving via the vagus nerve from the gut (stomach distension, nutrient detection) and converts them into behavioural responses like stopping eating. NTS neurons express GLP-1 receptors. When semaglutide activates them, it amplifies the fullness signals the gut is already sending. [3]

Research published between 2020 and 2024 suggests that the hindbrain (area postrema + NTS) may be the primary driver of appetite suppression, rather than the hypothalamus alone. Studies selectively ablating GLP-1R-expressing NTS neurons disrupted semaglutide's appetite-reducing effects more completely than ablating hypothalamic targets. This is an active area of research, but the takeaway is that treating semaglutide as primarily a "hypothalamic drug" undersells the brainstem's role. [3]

The hypothalamus: hunger and satiety neurons

The hypothalamus contains two groups of neurons that act as opposing hunger switches. AgRP neurons (agouti-related peptide) produce hunger signals that push you to eat. POMC neurons (pro-opiomelanocortin) produce satiety signals via the melanocortin pathway that push you to stop. Semaglutide inhibits AgRP neurons and activates POMC neurons, shifting the balance toward satiety. [2]

This matters particularly for long-term weight maintenance. When people lose weight through calorie restriction alone, AgRP neuron activity tends to rebound: the body increases hunger as a compensatory response to weight loss. Semaglutide's ongoing suppression of AgRP neurons blunts this rebound, which is part of why weight maintenance is substantially better on semaglutide than off it.

How GLP-1 signalling works inside brain neurons

The same cAMP/PKA signalling cascade that triggers insulin secretion in pancreatic beta cells operates inside neurons. When semaglutide binds GLP-1R on a brain neuron, cAMP rises, activating downstream signalling that changes the neuron's firing rate and synaptic connections. In the NTS, this increases inhibitory output to feeding-promoting circuits. In the arcuate nucleus (part of the hypothalamus), it suppresses AgRP and activates POMC. These are measurable neurological changes: c-Fos (a marker of neuronal activation) increases in NTS and hypothalamic nuclei after GLP-1R agonist administration. [2]

Why Semaglutide Works Once a Week: The Pharmacokinetics

Native GLP-1 lasts two minutes. Semaglutide lasts seven days. That difference is entirely due to three structural modifications made during its development at Novo Nordisk. [9]

The albumin binding is the key mechanism for the long half-life. Semaglutide is more than 99% bound to plasma albumin in circulation. Albumin molecules are large and cannot be filtered by the kidneys, so semaglutide effectively hitches a ride on albumin and escapes renal clearance. Only the small fraction that is unbound is active at any moment, creating a slow-release reservoir effect. [1]

What this means for your dosing schedule

With a half-life of approximately seven days, it takes four to five weeks (four to five half-lives) to reach steady-state concentration, the point where the amount added each week roughly equals the amount cleared. Before steady state, drug levels are still building. After stopping semaglutide, levels take approximately 23 days to fall below 10% of steady state. [11]

This explains several things you might notice in practice: why the first few weeks feel different from weeks four and beyond, why dose increases take a month to fully kick in, and why effects linger for weeks after stopping. The semaglutide calculator on GLP3 Planner lets you visualise exactly how concentration builds over your specific dosing schedule, including how long it takes to reach steady state after each dose change. For more on steady-state pharmacokinetics, see the understanding pharmacokinetics guide.

What All This Means for Weight Loss

The pancreatic, gastrointestinal, and central nervous system mechanisms work together to produce a sustained calorie deficit. You eat less (brain and gut satiety), absorb nutrients more slowly (gastric emptying delay), and have better blood glucose regulation (pancreatic effects). Over time, this adds up.

The STEP 1 trial (1,961 adults with obesity or overweight, 68 weeks) found a mean weight loss of 14.9% with semaglutide 2.4 mg vs 2.4% with placebo. The Friedrichsen et al. RCT found approximately 24% reduction in caloric intake relative to placebo, which is the mechanistic upstream cause. [6] [5]

For full clinical outcomes, trial timelines, and what weight loss typically looks like week-by-week, see semaglutide weight loss results. The mechanism is the focus here; the clinical data lives there.

Beyond Blood Sugar: Cardiovascular Effects

Two large trials established that semaglutide reduces major cardiovascular events beyond what weight loss or glucose control alone would explain.

• SUSTAIN-6 (type 2 diabetes, 3,297 patients): hazard ratio 0.74 for major adverse cardiovascular events (MACE), meaning a 26% relative risk reduction. [7]
• SELECT (non-diabetic adults with obesity and established cardiovascular disease, 17,604 patients): hazard ratio 0.80 for MACE, a 20% relative risk reduction in people without diabetes where glucose-lowering cannot explain the benefit. [8]

The mechanism behind the SELECT result is not fully understood. Proposed pathways include: anti-inflammatory effects (reduced C-reactive protein), improvements in vascular endothelial function, plaque stabilisation, reduced blood pressure, and improved lipid profiles. These are areas of active investigation, not established mechanisms. The clinical benefit is real; the exact reason it occurs at the cardiovascular level is still being worked out. [3]